News for VACCIBODY AS (VACC-ME.OL)

Jul 12, 2021 / 02:00PM GMTMichael Thyring Engsig - Vaccibody AS - CEO So good afternoon and good morning to our guests and listeners from the U.S. I'm Michael E

The growth of the market for Neoantigen cancer vaccines is primarily attributable to rapid technological advancements and improvements in the healthcare...

/PRNewswire/ -- DelveInsight's Genital Herpes Market Insights report includes a comprehensive understanding of current treatment practices, genital herpes...

Human Papillomavirus Associated Cancer Pipeline constitutes 50+ key companies continuously working towards developing 50+ Human Papillomavirus Associated...

Adaptive Biotechnologies sports a market-leading advantage with its one-of-a-kind proprietary tech. Read why I rate the ADPT stock a Buy for long-term investors.

The current chemotherapy-dominated landscape of cervical cancer treatment is set to change to include multiple different drug classes. ...

/PRNewswire/ -- DelveInsight's HPV 16+ Cancer Market report offers comprehensive coverage of the current treatment practices, pipeline drugs, HPV 16+ Cancer...